Welcome to our dedicated page for EPZM news (Ticker: EPZM), a resource for investors and traders seeking the latest updates and insights on EPZM stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EPZM's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EPZM's position in the market.
Epizyme (NASDAQ: EPZM) reported a net revenue of $13.0 million for Q2 2021, up from $2.5 million year-over-year. TAZVERIK generated $8.0 million, driven by $4.8 million in sales and $3.2 million from clinical trial supply. Despite a 20% workforce reduction, Epizyme aims to optimize its commercial strategy while reducing operational expenses to $220-$230 million for the year. A partnership with HutchMed will provide $25 million upfront and potential future payments up to $285 million. The company's net loss was $64.4 million, or $0.63 per share.
Epizyme and HUTCHMED announced a collaboration to develop and commercialize TAZVERIK® in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan. TAZVERIK® is an FDA-approved EZH2 methyltransferase inhibitor for certain patients with epithelioid sarcoma and follicular lymphoma. Epizyme will receive a $25 million upfront payment, with potential milestone payments of up to $285 million, plus royalties. HUTCHMED will lead clinical trials and commercialization in the region, aiming to expand TAZVERIK®'s reach and potential applications.
Epizyme (Nasdaq: EPZM) will host a conference call on August 9, 2021, at 8:30 a.m. ET to discuss its second quarter 2021 financial results and provide a business update. The call can be accessed by dialing (877) 844-6886 for domestic participants or (970) 315-0315 for international attendees, using conference ID 3658407. A live webcast will be available on Epizyme's investor website and archived for 60 days. The company focuses on novel epigenetic therapies and has one FDA-approved product, TAZVERIK®, for specific cancer treatments.
Epizyme (Nasdaq: EPZM) has launched the EZH2Now Testing Program in collaboration with Quest Diagnostics to provide EZH2 mutation testing for patients with relapsed or refractory follicular lymphoma. This initiative aims to enhance access to critical single gene testing, addressing a gap in existing Next Generation Sequencing options. The program allows eligible patients to receive testing services at no cost. This collaboration emphasizes Epizyme's commitment to improving patient care and supports oncologists in tailoring treatment plans based on genetic insights.
Epizyme (Nasdaq: EPZM) announced that its President and CEO, Robert Bazemore, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 2:30 p.m. ET. A live webcast will be available on the Company’s investor website, with an archive accessible for 60 days post-event.
Epizyme is focused on developing innovative epigenetic therapies, including its FDA-approved product TAZVERIK (tazemetostat) for certain cancer indications.
Epizyme, Inc. (Nasdaq: EPZM) announced new preclinical and clinical data presentations scheduled for June medical meetings. Key highlights include an oral presentation on SETD2 inhibitor data for multiple myeloma, aimed at advancing its SETD2 inhibitor program. Additionally, safety and preliminary activity data of tazemetostat in Epithelioid Sarcoma will be shared at ASCO. The company remains on track for an IND submission in mid-2021 and plans to initiate a first-in-human clinical trial by year-end. TAZVERIK continues to show promise in its approved indications, with ongoing trials exploring its efficacy across various cancers.
Epizyme (Nasdaq: EPZM) reported a significant first quarter 2021, achieving net revenues of $7.6 million, a 437% increase from $1.4 million year-over-year. The company's primary product, TAZVERIK, saw a 37% revenue growth from Q4 2020, driven by increased adoption in follicular lymphoma. Operating expenses rose to $72 million, resulting in a net loss of $70.3 million, compared to $50.9 million in the same period last year. Epizyme expects to maintain a cash runway into 2023 and anticipates adjusted operating expenses for 2021 between $235 and $255 million.
Epizyme (Nasdaq: EPZM) is set to host a conference call and webcast on May 6, 2021, at 7:30 a.m. ET to discuss its first quarter 2021 financial results and business updates. The company, focused on novel epigenetic therapies, has one FDA-approved product, TAZVERIK® (tazemetostat), indicated for certain types of cancer. Continued approval for TAZVERIK is contingent upon clinical benefit verification in further trials. Join the call by dialing (877) 844-6886 for domestic or (970) 315-0315 for international access.
Epizyme (Nasdaq: EPZM) hosted a call discussing its strategic vision focused on oncology and the development of its epigenetic therapies, particularly TAZVERIK. The drug has received accelerated approvals for treating epithelioid sarcoma and follicular lymphoma. Early data from ongoing trials show promising results, including high response rates in patients. Epizyme is also advancing its SETD2 inhibitor program and plans to initiate new basket trials for additional tumors in the latter half of 2021. The company emphasized its financial stability to support these initiatives through 2023.
Epizyme (Nasdaq: EPZM) has announced a strategic vision call scheduled for March 2, 2021, at 10:00 a.m. ET. The event will cover key topics, including the company's direction for 2021 and beyond, the role of epigenetics in oncology, and the development of its product, TAZVERIK. Investors can register for the call or access a live webcast through the company's website. Epizyme aims to innovate cancer treatment with its FDA-approved product and ongoing research pipeline.
FAQ
What is the market cap of EPZM (EPZM)?
